Active substances
Bacitracin zinc + Polymyxin b
- US FDA 7
- Health Canada 5
US FDA United States — FDA approvals (Drugs@FDA)
| Product | Strength | Form · route | Applicant | Status | First approved |
|---|---|---|---|---|---|
| BACITRACIN ZINC AND POLYMYXIN B SULFATE | 500 UNITS/GM;10,000 UNITS/GM | ointment · ophthalmic | BAUSCH AND LOMB INC | Prescription | 26 Jan 1995 |
| POLYSPORIN | 500 UNITS/GM;10,000 UNITS/GM **Federal Register determination that product was not discontinued or withdrawn for s or e reasons** | ointment · ophthalmic | MONARCH PHARMS | Discontinued | 16 Apr 1974 |
| BACITRACIN ZINC AND POLYMYXIN B SULFATE | 500 UNITS/GM;10,000 UNITS/GM | ointment · ophthalmic | SCIEGEN PHARMS | Discontinued | 30 Jan 1995 |
| BACITRACIN ZINC AND POLYMYXIN B SULFATE | 500 UNITS/GM;10,000 UNITS/GM | ointment · ophthalmic | PADAGIS US | Discontinued | 27 Feb 2002 |
| OCUMYCIN | 500 UNITS/GM;10,000 UNITS/GM | ointment · ophthalmic | PHARMAFAIR | Discontinued | |
| BACITRACIN ZINC-POLYMYXIN B SULFATE | 500 UNITS/GM;10,000 UNITS/GM | ointment · topical | NASKA | Discontinued | |
| POLYSPORIN | 10,000 UNITS/GM;2,000,000 UNITS/GM | aerosol · topical | GLAXOSMITHKLINE | Discontinued |
Canada Canada — marketed products (Health Canada)
| Brand | DIN | Strength | Form · route | Company |
|---|---|---|---|---|
| ANTIBIOTIC OINTMENT USP | 02230251 | 500 UNIT / G; 10000 UNIT / G | OINTMENT · TOPICAL | TARO PHARMACEUTICALS INC |
| BAND-AID BRAND ADHESIVE BANDAGES PLUS ANTIBIOTIC | 02236954 | 500 UNIT / G; 10000 UNIT / G | PAD; OINTMENT · TOPICAL | KENVUE CANADA INC. |
| POLYDERM OINTMENT USP | 02181908 | 500 UNIT / G; 10000 UNIT / G | OINTMENT · TOPICAL | TARO PHARMACEUTICALS INC |
| POLYSPORIN ANTIBIOTIC OINTMENT | 02237227 | 500 UNIT / G; 10000 UNIT / G | OINTMENT · TOPICAL | KENVUE CANADA INC. |
| STERISPORIN | 02359928 | 10000 UNIT / G; 500 UNIT / G | OINTMENT · OPHTHALMIC | STERI-MED PHARMA INC. |
Components
Values as published by each source: SFDA human drug list (4-2026, as published by the Council of Health Insurance; indications from the CHI Daman Drug Formulary), Drugs@FDA, EMA medicines data, Health Canada Drug Product Database (Open Government Licence – Canada), CMS NADAC, NHS Drug Tariff Part VIIIA (NHSBSA Copyright, Open Government Licence v3.0), WHO Model List of Essential Medicines (CC BY 3.0 IGO; regrouped by active substance, not created by WHO), EMA PRAC, US FDA safety-related labeling changes and MHRA Drug Safety Update (Open Government Licence v3.0). Sources and reuse. Not a substitute for the official registers or the product information.